Waters said this week that Douglas Berthiaume plans to retire from his position as CEO of the company sometime in the next two years.
The company's board of directors has appointed a succession planning committee to lead the selection of a successor, and it plans to hire an executive search firm. Waters said it plans to consider candidates who are already with the company and external candidates as well.
Berthiaume was appointed president and CEO of Waters in 1994, when the business was split from Millipore, and he took on the role of chairman in 1996. During his tenure, Waters said, the company has seen a 500 percent increase in revenues and a 25-fold increase in its share price since its IPO in 1995.
Biotheranostics has added three new members to its senior management team, including Gail Sloan as CFO, Macey Johnson as VP of managed care and reimbursement, and Matt Sargent as Breast Cancer Index commercialization leader.
Sloan previously was assistant controller at Affymax Research Institute, where she helped lead the spinoff of Affymetrix, and she was CFO and VP of finance at La Jolla Pharmaceutical. Johnson formerly worked at Genomic Health, where he developed managed care messaging and strategy for molecular assays, and he worked at Genentech, where he helped launch Avastin, Herceptin, and Tarceva.
Sargent recently was VP of oncology sales for Caris Life Sciences, where he built and trained the oncology sales team, and he has held senior sales and marketing positions at Exiqon Diagnostics and MedTrust Online.